Top Industry Leaders in the Erectile Dysfunction Drugs Market
Petros Pharmaceuticals launched two self-selection studies for its ED medication STENDRA (avanafil) in January 2022. These studies aim to gather patient preferences and improve treatment decisions.
Lupin Limited received FDA approval to market Sildenafil for oral suspension, 10 mg/mL, in September 2022. This new formulation caters to patients with swallowing difficulties.
Teva Pharmaceutical Industries announced Phase 3 results for its PDE5 inhibitor, Vestra, in May 2023. These results demonstrated efficacy and tolerability, potentially paving the way for market entry.
Apricus Biosciences launched Vitaros (testosterone gel) in the US in 2022. This new topical option expands treatment options for men with low testosterone contributing to ED.
List of Erectile Dysfunction Drugs Key Companies in the Market
-
Pfizer Inc. (U.S)
-
Apricus Biosciences Inc. (U.S).
-
Bayer AG (Germany)
-
Dong–A Pharmaceutical Co. Ltd. (South Korea)
-
S.K. Chemicals Co. Ltd. (South Korea)
-
Eli Lily & Co. (U.S)
-
Apricus Biosciences Inc. (U.S)
-
Cristalia Produtos Quimicos Farmaceuticos Ltd.
-
Meda Pharmaceuticals, Inc.
-
S.K. Chemicals Co. Ltd.
-
Vivus Inc.
-
Teva Pharmaceutical Industries Ltd